All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Solid tumors have been a tougher nut to crack for CAR T cells than B-cell cancers, for two main reasons. Solid tumors have an inhibitors microenvironment that has made it difficult to get durable responses. And identifying antigens as specific as the B-cell markers CD19 and CD22 has been challenging, leading to problems with on-target, off-tumor toxicity.
New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research annual meeting, including: Akeso, Ascentage, Celsion, Foghorn, Onconano.
New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research annual meeting, including: Alpine, Apexigen, Basilea, Biopath, CG, Chemocentryx, Cstone, Deciphera, Erasca, Gritstone, Highlight, Kineta, Mustang, Neoimmunetech, Neoleukin, Oric, Portage, Sotio, Trishula.
